Sat, Aug 2, 2014, 5:48 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Celldex Therapeutics, Inc. Message Board

  • nickdidomenico nickdidomenico Apr 3, 2014 9:49 AM Flag

    LONG VRTS Rindo versus Aldo

    what happens to Rindo prospects if Cytr's aldo shows strong results in P2 Glio study latter this year?

    Rindo is expensive where aldo is cheap.

    aldo human mouse model results are strong. if Aldo crosses the BBB, it could be lights out on Rindo even before it gets fda approval.

    I am hedged.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • What about some other random company's glib drug in phase 1? What if that's successful?

    • Not to worry, The Celldex vaccine has been shown to be quite effective in mice:
      "Peptide vaccination was also sufficiently potent to have marked efficacy against intracerebral tumors, resulting in a 173% increase in median survival time, with 80% of the C3H mice achieving long-term survival (P = 0.014)." -- Those Duke folks (2003)

      Note that these mice were not even pre-screened for v3 status.

      With these outstanding data and low side-effect profile CLDX need not concede any ground in the rodent glioblastoma market, especially not to a punk company like CYTR.

 
CLDX
12.96-0.13(-0.99%)Aug 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.